Oppenheimer & CO Inc Cellectis S.A. Transaction History

Oppenheimer & CO Inc

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 06, 2024	BUY	$2.41 - $3.09 $1,800 - $2,308	747 Added 0.56%	133,890 $354,000
Q4 2023 Feb 13, 2024	BUY	$0.97 - $3.55 $11,371 - $41,616	11,723 Added 9.65%	133,143 $410,000
Q3 2023 Nov 07, 2023	BUY	$1.58 - $2.86 $5,894 - $10,670	3,731 Added 3.17%	121,420 $191,000
Q2 2023 Aug 02, 2023	BUY	$1.72 - $2.12 $2,624 - $3,235	1,526 Added 1.31%	117,689 $231,000
Q1 2023 May 10, 2023	BUY	$1.83 - $3.84 $75,233 - $157,866	41,111 Added 54.78%	116,163 $224,000
Q4 2022 Feb 07, 2023	SELL	$1.85 - $2.6 $31,285 - $43,968	-16,911 Reduced 18.39%	75,052 $157,000
Q3 2022 Nov 14, 2022	BUY	$2.29 - $4.08 $37,395 - $66,626	16,330 Added 21.59%	91,963 $211,000
Q2 2022 Aug 08, 2022	BUY	$2.39 - $4.93 $2,339 - $4,826	979 Added 1.31%	75,633 $214,000
Q1 2022 May 12, 2022	BUY	$3.45 - $8.77 $257,556 - $654,715	74,654 New	74,654 $339,000
Q4 2018 Jan 29, 2019	SELL	$15.58 - $28.41 $428,434 - $781,246	-27,499 Closed	0 $0
Q3 2018 Oct 26, 2018	SELL	$25.99 - $30.6 $61,414 - $72,307	-2,363 Reduced 7.91%	27,499 $776,000
Q2 2018 Aug 10, 2018	BUY	$27.78 - $38.53 $829,566 - $1.15 Million	29,862 New	29,862 $845,000

10.8M

5.9K

1.4K

Ticker CLLS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,510,800
Market Cap $71M
Description
Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...

Get notified when there are updates to the investment portfolio of Oppenheimer & CO Inc, based on Form 13F filings with the SEC.

Stay updated on Oppenheimer & CO Inc with notifications on news.